Comparison of Localized Gastric Mucosa‐Associated Lymphoid Tissue (MALT) Lymphoma with and without <i>Helicobacter pylori</i> Infection

Akamatsu, Taiji; Mochizuki, Taro; Okiyama, Yoko; Matsumoto, Akihiro; Miyabayashi, Hideharu; Ota, Hiroyoshi

doi:10.1111/j.1523-5378.2006.00382.x

Cited by 56 publications

(59 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In order to determine the indication for second-line therapy in NR patients, some biological markers for the prediction of subsequent transformation would be useful in the clinical practice. It has been reported that the presence of the API2-MALT1 chimeric transcript, which is a useful marker for poor responsiveness to eradication therapy, could also represent the nature of the gastric MALT lymphoma Akamatsu et al 2006). Consistent with these reports, 3 of 4 NR patients (all 3 are H. pylorinegative) in the present study were positive for the API2-MALT1 chimera gene.…”

Section: Discussionsupporting

confidence: 81%

“…The patient's stomach had not shown gastric atrophy endoscopically and histologically before eradication, which is known to occasionally prevent the detection of H. pylori infection leading to false H. pylori-negatives. Such resistance to the bacterial eradication therapy in H. pylori-negative gastric MALT lymphoma is consistent with previous reports (Akamatsu et al 2006;Nakamura et al 2006). Conversely, Raderer et al (2006) have recently demonstrated that H. pylori eradication therapy was effective in 4 of 6 (67%) patients with H. pylori-negative gastric MALT lymphoma although, in their report, the API2-MALT1 chimeric transcript was detected in only 1 of 6 patients.…”

Section: Discussionsupporting

confidence: 69%

See 1 more Smart Citation

Long-Term Outcomes of Gastric Mucosa-Associated Lymphoid Tissue Lymphomas after Helicobacter pylori Eradication Therapy

Terai

Iijima

Kato

et al. 2008

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Mucosa-associated lymphoid tissue (MALT) lymphomas are localized primarily in the gastrointestinal tract and are characterized by an indolent nature and favorable outcome with specifi c therapy. Gastric MALT lymphomas are closely linked to Helicobacter pylori (H. pylori) infection, for which eradication therapy is recognized as an effective primary treatment for the disease. However, there is little information about long-term outcomes after the therapy. In the present study, we elucidated the long-term outcomes of 74 patients (70 H. pylori-positive and 4 negative cases) followed up by endoscopy at least 12 months after exclusive eradication therapy alone. The median follow-up period was 46 months. When the remission status was estimated at the time point of 12 months post-eradication, the numbers of patients with complete remission (CR), histologically residual disease with macroscopic normalization (hRD), partial remission with more than 50% tumor reduction (PR) or no response (NR) were 56, 12, 2 and 4, respectively. During follow-ups of over 12 months post-eradication, 11 of the 12 hRD cases were belatedly induced to CR but one CR case histologically relapsed into hRD. One of the 2 PR cases eventually turned into hRD 20 months later. Therefore, 66 CR, 3 hRD, 1 PR, and 4 NR cases (including 3 H. pylorinegative) were identifi ed at the last follow-up of the present study. All 74 patients were followed up without any second-line therapies, but none exhibited disease progression. Thus, the long-term outcome of localized gastric MALT lymphoma after H. pylori eradication therapy was favorable. A watch and wait strategy may be a reasonable approach for hRD since the majority might be in the process of turning into delayed CR. gatric MALT lymphoma; H. pylori eradication; long-term outcome; complete remission; radiotherapy.Tohoku

show abstract

Section: Discussionsupporting

confidence: 81%

Section: Discussionsupporting

confidence: 69%

Long-Term Outcomes of Gastric Mucosa-Associated Lymphoid Tissue Lymphomas after Helicobacter pylori Eradication Therapy

Terai

Iijima

Kato

et al. 2008

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

show abstract

“…This was the highest reported response rate among H. pylori-negative gastric MALT lymphomas. The response rate decreased to 46% in their later study [52] , but this was still relatively high compared with other reports [3,[46][47][48][49][50] . Contrary to these reports, earlier studies reported that H. pylorinegative gastric MALT lymphomas did not respond to antibiotic therapy [14,30,45] .…”

Section: Treatmentcontrasting

confidence: 54%

“…The first-line treatment for H. pylori-negative gastric MALT lymphomas is also antibiotic therapy [36] . Even in the absence of H. pylori infection, several studies have reported that certain proportions of patients responded to this antibiotic therapy [3,4,14,30,[45][46][47][48][49][50][51][52] (Table 2). …”

Section: Treatmentmentioning

confidence: 99%

“…Steinbach et al [45] (1999) 0/6 (0) Ruskoné-Fourmestraux et al [30] (2001) 0/10 (0) Ye et al [14] (2003) 0/5 (0) Nakamura et al [3] (2006) 2/7 (29) Raderer et al [4] (2006) 5/6 (83) Akamatsu et al [46] (2006) 1/9 (11) Terai et al [47] (2008) 1/4 (25) Park et al [48] (2010) 3/4 (75) Asano et al [49] (2012) 5/17 (29) Choi et al [50] (2013) 2/5 (40) Raderer et al [52] (2015) 5/13 (46) but there are several possible speculations. One speculation, as mentioned above, is that these patients were infected with bacteria other than H. pylori, and the antibiotic eradication therapy for H. pylori was able to eradicate this non-H. pylori bacteria [24] .…”

Section: Responding Patients/treated Patients (Responding Rate)mentioning

confidence: 99%

See 1 more Smart Citation

Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphomas: A review

Asano

Iijima

Koike

et al. 2015

WJG

View full text Add to dashboard Cite

Since Isaacson and Wright first reported on the extranodal marginal zone B-cell lymphoma of the stomach in 1983, following studies have clarified many aspects of this disease. We now know that the stomach is the most affected organ by this disease, and approximately One possibility is that genetic alterations result in nuclear factor-kappa B (NF-κB) activation. Among these alterations, t(11;18)(q21;q21) is more frequently observed in H. pylori -negative gastric MALT lymphomas, and such translocation results in the synthesis of fusion protein API2-MALT1, which causes canonical and noncanonical NF-κB activation. Another possibility is infection with bacteria other than H. pylori . This could explain why H. pylori eradication therapy can cure some proportions of H. pylori -negative gastric MALT lymphoma patients, although the bacteria responsible for MALT lymphomagenesis are yet to be defined. Recent advances in endoscopy suggest magnifying endoscopy with narrow band imaging as a useful tool for both detecting gastric MALT lymphoma lesions and judging the response to treatment. A certain proportion of H. pylori -negative gastric MALT lymphoma patients respond to eradication therapy; hence, H. pylori eradication therapy could be considered as a first-line treatment for gastric MALT lymphomas regardless of their H. pylori infection status.

show abstract

Time trends and survival of marginal zone lymphoma over 25 years in Girona, Spain (1994–2018)

et al. 2023

View full text Add to dashboard Cite

Objective To analyze the incidence, incidence trends, and survival of marginal zone lymphomas (MZLs) in Girona and to describe these indicators based on the location in the case of extranodal MZLs. Methods Population‐based study of MZL collected in the Girona Cancer Registry, 1994–2018. Sociodemographic data, tumor location, and stage were obtained from clinical records. Crude (CR) and age‐adjusted (ASRE) incidence rates expressed per 100,000 person‐years (p‐y) were calculated. Joinpoint regression models were used for the trend analysis according to the MZL group. Five‐year observed and net survival were analyzed. Results A total of 472 MZLs were included, 44 (9.3%) were nodal, 288 (61.0%) extranodal, 122 (25.9%) splenic, and the rest (n = 18) MZL, NOS. The CR for the MZL was 2.89 × 100,000 p‐y (95% CI: 2.63–3.15), the ASRE was 3.26 × 100,000 p‐y (95% CI: 2.97–3.57), and the annual percentage change (APC) was 1.6 (95% CI: 0.5–2.7). The ASRE for nodal MZL was 0.30 × 100,000 p‐y (95% CI: 0.22–0.41) and showed an APC of 2.9% (95% CI: −16.4–26.6). For extranodal MZL, the ASRE was 1.98 × 100,000 p‐y (95% CI: 1.76–2.23) and the APC was −0.4 (95% CI: −2.0–1.2). The most frequent locations of this type of MZL were the gastric (35.4%), skin (13.2%), and respiratory system (11.8%). The ASRE of the splenic MZL was 0.85 (95% CI: 0.71–1.02) with an APC of 12.8 (95% CI: 2.5–24.0). The 5‐year net survival of MZL was 82.1% (95% CI: 76.3–86.5). Conclusions This study reveals differences in the incidence and trend of the incidence of MZL according to the subgroup, showing a significant increase in the overall MZL mainly due to splenic MZL type.

show abstract

Comparison of Localized Gastric Mucosa‐Associated Lymphoid Tissue (MALT) Lymphoma with and without Helicobacter pylori Infection

Cited by 56 publications

References 26 publications

Long-Term Outcomes of Gastric Mucosa-Associated Lymphoid Tissue Lymphomas after Helicobacter pylori Eradication Therapy

Long-Term Outcomes of Gastric Mucosa-Associated Lymphoid Tissue Lymphomas after Helicobacter pylori Eradication Therapy

Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphomas: A review

Time trends and survival of marginal zone lymphoma over 25 years in Girona, Spain (1994–2018)

Contact Info

Product

Resources

About